Pub Date : 2026-02-28DOI: 10.1016/S0140-6736(25)02644-3
Cinzia Dello Russo, Luigi Venetucci, Ronnie Ramlogan, Dimitri Gagliardi, Abisobe Akintola, Munir Pirmohamed
{"title":"Clopidogrel versus aspirin for coronary artery disease.","authors":"Cinzia Dello Russo, Luigi Venetucci, Ronnie Ramlogan, Dimitri Gagliardi, Abisobe Akintola, Munir Pirmohamed","doi":"10.1016/S0140-6736(25)02644-3","DOIUrl":"https://doi.org/10.1016/S0140-6736(25)02644-3","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10531","pages":"852-853"},"PeriodicalIF":88.5,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-28DOI: 10.1016/S0140-6736(26)00289-8
Ronald Labonté, Chiara Bodini
{"title":"Watching the watchers: a reply from Global Health Watch 7.","authors":"Ronald Labonté, Chiara Bodini","doi":"10.1016/S0140-6736(26)00289-8","DOIUrl":"https://doi.org/10.1016/S0140-6736(26)00289-8","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10531","pages":"849-850"},"PeriodicalIF":88.5,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-28DOI: 10.1016/S0140-6736(25)02645-5
Ahmed Ibrahim, Laila Shalabi, Giuseppe Andó
{"title":"Clopidogrel versus aspirin for coronary artery disease.","authors":"Ahmed Ibrahim, Laila Shalabi, Giuseppe Andó","doi":"10.1016/S0140-6736(25)02645-5","DOIUrl":"https://doi.org/10.1016/S0140-6736(25)02645-5","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10531","pages":"853"},"PeriodicalIF":88.5,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-26DOI: 10.1016/S0140-6736(26)00415-0
Sharmila Devi
{"title":"Health and war in Sudan.","authors":"Sharmila Devi","doi":"10.1016/S0140-6736(26)00415-0","DOIUrl":"https://doi.org/10.1016/S0140-6736(26)00415-0","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":" ","pages":""},"PeriodicalIF":88.5,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1016/S0140-6736(26)00307-7
Chloe Orkin, Peter J Ruane, Malcolm Hedgcock, Cyril Gaultier, Marcelo H Losso, Benoit Trottier, Thomas Lutz, Mark O'Reilly, Mark Bloch, Jihad Slim, Moti Ramgopal, Simiso Sokhela, Karam Mounzer, Hung-Chin Tsai, Jorge Santana Bagur, Xu Zhang, Keith Aizen, Kwanza Price, Nicolas Margot, Jairo M Montezuma-Rusca, Peter Sklar, Martin Rhee, Pedro Cahn
Background: Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1.
Methods: ARTISTRY-1 was a randomised, open-label, active-controlled, non-inferiority phase 3 trial conducted at hospitals and clinics across 15 countries that enrolled people with HIV-1 with virological suppression on complex regimens. Participants were randomly assigned (using interactive technology, 2:1, stratified by geographical region) to switch to once-daily oral bictegravir-lenacapavir 75 mg/50 mg STR or continued complex regimen. The primary outcome was the proportion of participants with an HIV-1 RNA viral load of 50 copies per mL or higher at week 48 (US Food and Drug Administration Snapshot algorithm), assessed in all randomly assigned participants who received any dose of assigned treatment. This trial (active; enrolment complete) was registered with ClinicalTrials.gov (NCT05502341).
Findings: Between Jan 29 and Sept 26, 2024, 729 participants were screened; 557 were randomly assigned and treated (bictegravir-lenacapavir n=371; complex regimen n=186). At baseline, median age was 60 years (range 22-84), HIV treatment duration was 28 years (IQR 22-32); participants were taking a median of three antiretroviral pills per day (range 2-11). At week 48, an HIV-1 RNA viral load of 50 copies per mL or higher was observed in three (1%) participants receiving bictegravir-lenacapavir and two (1%) receiving a complex regimen (difference -0·3%; 95·002% CI -2·3 to 1·8), meeting the non-inferiority margin of 4%. No resistance emerged. Adverse event rates were similar between groups. Six (2%) participants discontinued bictegravir-lenacapavir and one (1%) discontinued their complex regimen due to adverse events. There were five deaths in the bictegravir-lenacapavir group, none of which were deemed related to study drug. Participants reported increased treatment satisfaction after switching to bictegravir-lenacapavir.
Interpretation: Bictegravir-lenacapavir STR demonstrated non-inferior efficacy to complex regimens, with a similar safety profile and increased treatment satisfaction. Bictegravir-lenacapavir offers new opportunities for HIV-1 treatment optimisation for people taking complex regimens.
{"title":"Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.","authors":"Chloe Orkin, Peter J Ruane, Malcolm Hedgcock, Cyril Gaultier, Marcelo H Losso, Benoit Trottier, Thomas Lutz, Mark O'Reilly, Mark Bloch, Jihad Slim, Moti Ramgopal, Simiso Sokhela, Karam Mounzer, Hung-Chin Tsai, Jorge Santana Bagur, Xu Zhang, Keith Aizen, Kwanza Price, Nicolas Margot, Jairo M Montezuma-Rusca, Peter Sklar, Martin Rhee, Pedro Cahn","doi":"10.1016/S0140-6736(26)00307-7","DOIUrl":"https://doi.org/10.1016/S0140-6736(26)00307-7","url":null,"abstract":"<p><strong>Background: </strong>Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1.</p><p><strong>Methods: </strong>ARTISTRY-1 was a randomised, open-label, active-controlled, non-inferiority phase 3 trial conducted at hospitals and clinics across 15 countries that enrolled people with HIV-1 with virological suppression on complex regimens. Participants were randomly assigned (using interactive technology, 2:1, stratified by geographical region) to switch to once-daily oral bictegravir-lenacapavir 75 mg/50 mg STR or continued complex regimen. The primary outcome was the proportion of participants with an HIV-1 RNA viral load of 50 copies per mL or higher at week 48 (US Food and Drug Administration Snapshot algorithm), assessed in all randomly assigned participants who received any dose of assigned treatment. This trial (active; enrolment complete) was registered with ClinicalTrials.gov (NCT05502341).</p><p><strong>Findings: </strong>Between Jan 29 and Sept 26, 2024, 729 participants were screened; 557 were randomly assigned and treated (bictegravir-lenacapavir n=371; complex regimen n=186). At baseline, median age was 60 years (range 22-84), HIV treatment duration was 28 years (IQR 22-32); participants were taking a median of three antiretroviral pills per day (range 2-11). At week 48, an HIV-1 RNA viral load of 50 copies per mL or higher was observed in three (1%) participants receiving bictegravir-lenacapavir and two (1%) receiving a complex regimen (difference -0·3%; 95·002% CI -2·3 to 1·8), meeting the non-inferiority margin of 4%. No resistance emerged. Adverse event rates were similar between groups. Six (2%) participants discontinued bictegravir-lenacapavir and one (1%) discontinued their complex regimen due to adverse events. There were five deaths in the bictegravir-lenacapavir group, none of which were deemed related to study drug. Participants reported increased treatment satisfaction after switching to bictegravir-lenacapavir.</p><p><strong>Interpretation: </strong>Bictegravir-lenacapavir STR demonstrated non-inferior efficacy to complex regimens, with a similar safety profile and increased treatment satisfaction. Bictegravir-lenacapavir offers new opportunities for HIV-1 treatment optimisation for people taking complex regimens.</p><p><strong>Funding: </strong>Gilead Sciences.</p>","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":" ","pages":""},"PeriodicalIF":88.5,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147321779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-21DOI: 10.1016/S0140-6736(25)02509-7
Francisco J Zagmutt, Jane G Pouzou, Flaminia Ortenzi, Gordon Guyatt, Andrew Mente, Ty Beal
{"title":"The EAT-Lancet Commission: issues and responses.","authors":"Francisco J Zagmutt, Jane G Pouzou, Flaminia Ortenzi, Gordon Guyatt, Andrew Mente, Ty Beal","doi":"10.1016/S0140-6736(25)02509-7","DOIUrl":"https://doi.org/10.1016/S0140-6736(25)02509-7","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10530","pages":"759-761"},"PeriodicalIF":88.5,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-21DOI: 10.1016/S0140-6736(26)00355-7
The Lancet
{"title":"Health on the front line: 4 years of war in Ukraine.","authors":"The Lancet","doi":"10.1016/S0140-6736(26)00355-7","DOIUrl":"https://doi.org/10.1016/S0140-6736(26)00355-7","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10530","pages":"733"},"PeriodicalIF":88.5,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-21DOI: 10.1016/S0140-6736(25)02507-3
Robert Fungo, Francis Zotor, Andrew Prentice, Habiba Hassan-Wassef, Muhammad Ali Dhansay, Hassan Aguenaou, Aloysius Maduforo, Kingsley K A Pereko, Given Chipili, Betrand Tambe, Augustin Zeba
{"title":"The EAT-Lancet Commission: issues and responses.","authors":"Robert Fungo, Francis Zotor, Andrew Prentice, Habiba Hassan-Wassef, Muhammad Ali Dhansay, Hassan Aguenaou, Aloysius Maduforo, Kingsley K A Pereko, Given Chipili, Betrand Tambe, Augustin Zeba","doi":"10.1016/S0140-6736(25)02507-3","DOIUrl":"https://doi.org/10.1016/S0140-6736(25)02507-3","url":null,"abstract":"","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":"407 10530","pages":"758-759"},"PeriodicalIF":88.5,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号